2026-04-13T01:07:21Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2015202025-12-05T10:06:07Zcom_2072_1057col_2072_478916col_2072_478917col_2072_478929

Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution Fröberg, Gabrielle Maurer, Florian P. Chryssanthou, Erja Fernström, Louise Benmansour, Hanaa Boarbi, Samira Mengshoel, Anne Torunn Keller, Peter M. Viveiros, Miguel Machado, Diana Fitzgibbon, Margaret M. Mok, Simone Werngren, Jim Cirillo, Daniela Maria Alcaide, Fernando Hyyryläinen, Hanne-Leena Aubry, Alexandra Andres, Sönke Nadarajan, Darshaalini Svensson, Erik Turnidge, John Giske, Christian G. Kahlmeter, Gunnar Cambau, Emmanuelle van Ingen, Jakko Schön, Thomas EUCAST AMST ESCMYC study groups Medicaments antibacterians Resistència als medicaments Micobacteris Antibacterial agents Drug resistance Mycobacteria Objective: For non-tuberculous mycobacteria (NTM), minimum inhibitory concentration (MIC) distributions of wild-type isolates have not been systematically evaluated despite their importance for establishing antimicrobial susceptibility testing (AST) breakpoints. Methods: We gathered MIC distributions for drugs used against the Mycobacterium avium complex (MAC) and Mycobacterium abscessus (MAB) obtained by commercial broth microdilution (SLOMYCOI and RAPMYCOI) from 12 laboratories. Epidemiological cut-off values (ECOFFs) and tentative ECOFFs (TECOFFs) were determined by EUCAST methodology including quality control (QC) strains. Results The clarithromycin ECOFF was 16 mg/L for M. avium (n=1271) whereas TECOFFs were 8 mg/L for M. intracellulare (n=415) and 1 mg/L for MAB (n=1014) confirmed by analysing MAB subspecies without inducible macrolide resistance (n=235). For amikacin, the ECOFFs were 64 mg/L for MAC and MAB. For moxifloxacin, the WT spanned >8 mg/L for both MAC and MAB. For linezolid, the ECOFF and TECOFF were 64 mg/L for M. avium and M. intracellulare, respectively. Current CLSI breakpoints for amikacin (16 mg/L), moxifloxacin (1 mg/L) and linezolid (8 mg/L) divided the corresponding WT distributions. For QC M. avium and M. peregrinum, ≥95% of MIC values were well within recommended QC ranges. Conclusion : As a first step towards clinical breakpoints for NTM, (T)ECOFFs were defined for several antimicrobials against MAC and MAB. Broad wild-type MIC distributions indicate a need for further method refinement which is now under development within the EUCAST subcommittee for anti-mycobacterial drug susceptibility testing. In addition, we showed that several CLSI NTM breakpoints are not consistent in relation to the (T)ECOFFs. 2023-08-25T11:53:59Z 2023-08-25T11:53:59Z 2023-02-20 2023-08-25T11:53:59Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Reproducció del document publicat a: https://doi.org/10.1016/j.cmi.2023.02.007 Clinical Microbiology and Infection, 2023, vol. 29, p. 758-764 https://doi.org/10.1016/j.cmi.2023.02.007 cc by (c) Fröberg, Gabrielle et al., 2023 https://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess European Society of Clinical Microbiology and Infectious Diseases Articles publicats en revistes (Patologia i Terapèutica Experimental)